News & Events

BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced the three winners of its Immunology Grant Program, who will receive grants totaling $100,000 to conduct innovative immunology research projects using the company’s research reagents. More than 200 researchers submitted abstracts for consideration.

“There are thousands of researchers with wonderful ideas that will advance the scientific understanding of disease. For many of them funding limitations for research reagents can be a tremendous hurdle,” said Robert Balderas, VP, R&D, BD Biosciences. “These grants reflect BD’s continuing commitment to innovation in research and development.”

2006 Grand Prize Winner awarded $50,000 worth of research reagents:

• Dan Ilkovitch of the University of Miami Miller School of Medicine

  Abstract title: Dissection of immune modulation by MUC1/sec or IEP, which enables induction of an effective anti-tumor immune response

2006 Honorable Mentions each awarded $25,000 worth of research reagents:

• Claudia Macaubas of Stanford University School of Medicine

Abstract title: Intracellular signaling networks in inflammation: a comparison of three diseases (juvenile idiopathic arthritis, Kawasaki Disease, polyarticular JIA) of childhood using BD Phosflow™ technology

• Patrizia Damonte of the University of California, Davis, Center for Comparative Medicine

Abstract title: Mammary cancer fate is determined in the pre-cancer stem cell

BD Biosciences notified the winners by telephone and posted their names and institutions, along with a list of the distinguished review panel, to http://www.bdbiosciences.com/grant. The winners were determined by a panel of outside scientific experts unaffiliated with BD Biosciences.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs more than 25,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit www.bd.com.